- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05714410
Evaluation of Changes in Bowel Movement Frequency Following the Consumption of PHGG Compared to Placebo (TYPHOON-02)
January 29, 2024 updated by: Société des Produits Nestlé (SPN)
Evaluation of Changes in Bowel Movement Frequency Following the Consumption of Partially Hydrolyzed Guar Gum (PHGG) in Adults With Constipation as Compared to Placebo (Typhoon 2)
Evaluation of Changes in Bowel Movement Frequency Following the Consumption of Partially Hydrolyzed Guar Gum (PHGG) in Adults With Constipation as Compared to Placebo (Typhoon 2)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
160
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cork, Ireland, T23 R50R
- Atlantia Food Clinical Trials
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Men or women aged 18-75.
Adapted Rome IV Criteria of functional constipation* or IBSconstipation** for a minimum of 3 months
*1-2 SBM/week and at least 1 of the following at least 30% of the time:
- Bristol stool scale 1-2
- Straining
- Sense of incomplete evacuation
- Sense of stool blockage
Need of digital maneuvers
- Subjects with IBS-C: the above constipation criteria + abdominal pain are allowed.
- Ability to understand the participant information sheet and instructions, and able to provide informed consent.
- Access to a suitable smartphone device (Android or iOS) with ability to download and complete the study e-Diary daily for the duration of the trial.
Exclusion Criteria:
- Pregnant women or breastfeeding.
- Organic chronic gastrointestinal disease or complication (such as, but not limited to, Inflammatory Bowel Disease, Microscopic colitis, Eosinophilic gastroenteritis, Radiation-related enterocolitis, Coeliac disease).
- Subjects with a diagnosed food allergy or hypersensitive to any of the components of the study product.
- Subjects with chronic diarrhea.
- Active peptic ulcer.
- Major gastrointestinal or colonic surgery (such as, gastric bypass or any other obesity or metabolic interventions including endoscopic procedures or devices, any gastro-intestinal or colonic resection); cholecystectomy and appendectomy are allowed.
- Neurologic or other clinically significant comorbid diseases that may affect gastrointestinal function, such as multiple sclerosis, spinal cord injury or Hirschsprung disease.
- Illness that may preclude the participant's ability to complete the study or that may confound the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness, severe cardiovascular disease, chronic renal failure or eating disorders) or any other serious illness resulting in >2 weeks inability to work in the 3 months before the study start.
- Participants with clinically significant (as per physician judgement) co-morbid illnesses such as cardiovascular, endocrine (e.g. hypothyroidism, diabetes), renal, or other chronicdisease (e.g. reduced mobility or increased fragility).
- Active alcohol, drug, or medication abuse (as per clinician judgement).
- Self-reported symptoms suggestive of pelvic organ prolapse as per clinician judgement, such as feeling of pressure or fullness in the pelvic area, intra vaginal discomfort, painful intercourse, and urinary problems.
- Moderate or severe active local anorectal problems such as recurrent anal fissures, frequent bleeding, large prolapsing hemorrhoids.
- Any clinically relevant abnormalities detected during the physical examination or any alarm features in the medical history such as sudden unintentional weight loss (>10% in 3 months), frequent rectal bleeding not caused by anal fissures or hemorrhoids, recent change in bowel habit (<3 months), severe abdominal pain and stool positive for occult blood.
- Regular (i.e. daily or weekly) use of PHGG within 6 months of screening.
- Participation in another study with any investigational product within 6 months of randomization for drug study and within 2 months of randomization for a nutritional study.
- Investigator believes that the participant is physically or mentally unfit to participate in the trial.
- Participants currently of childbearing potential, but not using an effective method of contraception, as determined by the investigator.
- Any participant who is an employee of the study site or an Atlantia Clinical Trials employee or their close family member or a member of their household.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: PHGG fiber
Partially Hydrolyzed Guar Gum (PHGG) in powder formulation, is to be consumed orally adding water or juice.
One serving per day.
|
PHGG
|
Placebo Comparator: Placebo Maltodextrin
Maltodextrin in powder formulation is to be consumed orally adding water or juice.
One serving per day.
|
PHGG
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Spontaneous Bowel Movements
Time Frame: 6 weeks
|
Change in mean weekly frequency of Spontaneous Bowel Movements (SBM) as measured by the daily bowel diary from baseline to end of treatment period.
Frequency will be defined as the mean weekly number of SBM during the 2-week run-in period prior to V0, for baseline, and during the final 2 weeks of the intervention period, for end of treatment.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in frequency of Complete Spontaneous Bowel Movements
Time Frame: 6 weeks
|
Change in mean weekly frequency of Complete Spontaneous Bowel Movements (CSBM) as measured by the daily bowel diary, from baseline to the end of treatment period.
|
6 weeks
|
Change in stool consistency
Time Frame: 6 weeks
|
Change in stool consistency as measured by the Bristol stool scale, from baseline to end of intervention.
The minimum and maximum values are 1 to 7. The extremes scores mean worse outcome.
The middle or the scale mean the better outcome.
|
6 weeks
|
Change in constipation related symptoms
Time Frame: 6 weeks
|
Change in constipation related symptoms from baseline to end of intervention as measured by the Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire.
The minimum and maximum values are 1 to 48.
The higher score means worse outcome.
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Martin Muckley, FRCPI, Altantia Food Clinical Trial
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 25, 2023
Primary Completion (Actual)
January 19, 2024
Study Completion (Actual)
January 19, 2024
Study Registration Dates
First Submitted
January 26, 2023
First Submitted That Met QC Criteria
January 26, 2023
First Posted (Actual)
February 6, 2023
Study Record Updates
Last Update Posted (Actual)
January 30, 2024
Last Update Submitted That Met QC Criteria
January 29, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22.08.CLI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation - Functional
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
Huazhong University of Science and TechnologyWuhan Union Hospital, China; Guangzhou University of Traditional Chinese Medicine and other collaboratorsUnknownFunctional Constipation | Functional DiarrheaChina
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Pamukkale UniversityRecruiting
-
Shanghai University of Traditional Chinese MedicineLonghua Hospital; Shanghai Municipal Hospital of Traditional Chinese MedicineRecruiting
-
Universidade Nova de LisboaCINTESIS - Center for Health Technology and Services ResearchRecruiting
-
United PharmaceuticalsDelta ConsultantsRecruitingFunctional ConstipationItaly
-
King's College LondonImperial College London; Queen Mary University of LondonRecruitingConstipation - FunctionalUnited Kingdom
-
Children's Hospital Los AngelesTerminatedFunctional ConstipationUnited States
Clinical Trials on PHGG
-
NestléCompletedEnteral NutritionUnited States
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruiting
-
NestléCompletedConstipation - FunctionalIreland
-
The University of Hong KongRecruiting
-
Société des Produits Nestlé (SPN)Recruiting
-
IRCCS San Raffaele RomaCompleted
-
Universiti Putra MalaysiaNational Cancer Institute, MalaysiaCompleted
-
Fu Jen Catholic University HospitalRecruitingMicrobial Colonization | COPD | Respiratory Tract DiseaseTaiwan